The physiopathological significance of ceruloplasmin: A possible therapeutic approach

Biochemical Pharmacology

Volumn 60, Issue 12, 2000, Pages 1735-1741

  Floris, Giovanni ^a   Medda, Rosaria ^a   Padiglia, Alessandra ^a   Musci, Giovanni ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Biogenic amines; Ceruloplasmin; Iron; Neurodiseases

Indexed keywords

CERULOPLASMIN; IRON; OXIDOPAMINE; OXYGEN DERIVATIVE;

CATALYSIS; HUMAN; IRON METABOLISM; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN BINDING; REACTION ANALYSIS; REGULATORY MECHANISM; REVIEW; STOICHIOMETRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; CERULOPLASMIN; HOMEOSTASIS; HUMANS; IRON; OXIDATION-REDUCTION; OXIDOPAMINE;

EID: 0034672639     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00399-3     Document Type: Review

References (93)

1. Investigations in serum copper. Isolation of the copper containing protein and a description of some of its properties
2. Purification and characterization of Fet3 protein, a yeast homologue of ceruloplasmin
3. Early and more recent history in the research of multi-copper oxidases
4. The state and function of copper in biological systems
5. High-potential states of blue and purple copper proteins
6. The influence of axial ligands on the reduction potential of blue copper proteins
7. Chicken ceruloplasmin. Evidence in support of a trinuclear cluster involving type 2 and 3 copper centers
8. X-ray crystal structure of the blue oxidase ascorbate oxidase from zucchini. Analysis of the polypeptide fold and a model of the copper sites and ligands
9. Structural and functional aspect of metal sites in biology
10. Molecular properties of ceruloplasmin from different species
11. Effect of pH on electron-paramagnetic-resonance spectra of ceruloplasmin
12. The stoichiometry of the paramagnetic copper and the oxidation-reduction potentials of type I copper in human ceruloplasmin
13. Ceruloplasmin
14. The state of the copper sites in human ceruloplasmin
15. The X-ray structure of human serum ceruloplasmin at 3.1 Å: Nature of the copper centres
16. Spectroscopic and magnetic studies of human ceruloplasmin: Identification of a redox-inactive reduced Type 1 copper site
17. On the lability and functional significance of the type 1 copper pool in ceruloplasmin
18. Ceruloplasmin: The copper transport protein with essential oxidase activity
19. Ceruloplasmin: The serum copper transport protein with oxidase activity
20. Perspectives on copper biochemistry
21. Evidence for ceruloplasmin as a copper transport protein
22. The biological role of ceruloplasmin and its oxidase activity
23. Regulation of aortic CuZn-superoxide dismutase with copper. Caeruloplasmin and albumin re-activate and transfer copper to the enzyme in culture
24. Regulation of Cu,Zn superoxide dismutase with copper. Caeruloplasmin maintains levels of functional enzyme activity during differentiation of K562 cells
25. Copper as a cofactor and regulator of copper,zinc superoxide dismutase
26. Copper transport from ceruloplasmin: Characterization of the cellular uptake mechanism
27. Ascorbate enhances copper transport from ceruloplasmin into human K562 cells
28. Specific receptor for ceruloplasmin in membrane fragments from aortic and heart tissues
29. Ceruloplasmin receptors in liver cell suspensions are limited to the endothelium
30. Purification and partial characterization of ceruloplasmin receptors from rat liver endothelium
31. Ceruloplasmin receptors of erythrocytes
32. Identification of ceruloplasmin receptors on the surface of human blood monocytes, granulocytes, and lymphocytes
33. The interaction of ceruloplasmin with Kupffer cells
34. Characterisation of the copper uptake mechanism and isolation of the ceruloplasmin receptor/copper transporter in human placental vesicles
35. Deficiency of ceruloplasmin in patients with hepatolenticular degeneration (Wilsons disease)
36. Cytochrome oxidase deficiency in Wilson's disease: A suggested ceruloplasmin function
37. Practical recommendations and new therapies for Wilson's disease
38. Treatment and management of Wilson's disease
39. The transport of copper
40. Copper transport
41. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration
42. Ceruloplasmin impairs endothelium-dependent relaxation of rabbit aorta
43. Inhibition of endothelial nitric-oxide synthase by ceruloplasmin
44. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
45. Ceruloplasmin stimulates thymidine incorporation by CCL-39 cells in the absence of serum or growth factors
46. Ceruloplasmin stimulates NADH oxidation of pig liver plasma membrane
47. Iron reverses impermeable chelator inhibition of DNA synthesis in CCl 39 cells
48. Caeruloplasmin: Acute-phase antioxidant
49. The antioxidants of human extracellular fluids
50. Intact human ceruloplasmin oxidatively modifies low density lipoprotein
51. Identification of the prooxidant site of human ceruloplasmin: A model for oxidative damage by copper bound to protein surfaces
52. Ceruloplasmin copper induces oxidant damage by a redox process utilizing cell-derived superoxide as reductant
53. The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum
54. Mobilization of liver iron by ferroxidase (ceruloplasmin)
55. The role of ceruloplasmin in iron metabolism
56. Ceruloplasmin and maternal iron mobilization
57. The biology of human ceruloplasmin
58. Aceruloplasminemia: Molecular characterization of this disorder of iron metabolism
59. Hereditary ceruloplasmin deficiency with hemosiderosis: A clinicopathological study of a Japanese family
60. Role of ceruloplasmin in cellular iron uptake
61. The FET3 gene of S. cerevisiae encodes a multicopper oxidase required for ferrous iron uptake
62. The FET3 gene product required for high affinity iron transport in yeast is a cell surface ferroxidase
63. An oxidase-permease-based iron transport system in Schizosaccharomyces pombe and its expression in Saccharomyces cerevisiae
64. Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism
65. Role of ceruloplasmin and ascorbate in cellular iron release
66. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux
67. A novel glycosylphosphatidylinositol-anchored form of ceruloplasmin is expressed by mammalian astrocytes
68. Glycosyl phosphatidylinositol-anchored ceruloplasmin is expressed by rat Sertoli cells and is concentrated in detergent-insoluble membrane fractions
69. Automated measurement of serum ferroxidase activity
70. Mitochondrial function is differentially affected upon oxidative stress
71. 2+-ATPase AT submicromolar iron concentrations: Evidence for metal-catalyzed oxidation
72. Cellular iron metabolism
73. Nitrosothiol formation catalyzed by ceruloplasmin. Implication for cytoprotective mechanism in vivo
74. Copper supplementation of adult men: Effects on blood copper enzyme activities and indicators of cardiovascular disease risk
75. The pH optimum for ceruloplasmin oxidase activity in the plasma of several species of animal
76. Modulation of the redox state of the copper sites of human ceruloplasmin by chloride
77. The multifunctional oxidase activity of ceruloplasmin as revealed by anion binding studies
78. Effect of ceruloplasmin on 6-hydroxydopamine oxidation
79. Studies related to the chemistry of melanins. XII. Some spectroscopic experiments regarding intermediates in melanogenesis
80. Inhibition of biogenic amine uptake by hydrogen peroxide: A mechanism for toxic effects of 6-hydroxydopamine
81. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents
82. Free radical-generated neurotoxicity of 6-hydroxydopamine
83. Some aspects of tyrosine secondary metabolism
84. Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease
85. Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease
86. Dopamine receptors - Physiological understanding to therapeutic intervention potential
87. 'Rational hope' in the early treatment of Parkinson's disease
88. Levodopa in Parkinson's disease: Neurotoxicity issue laid to rest?
89. Gene therapy for Parkinson's disease
90. Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimental parkinsonism
91. Dopamine turnover and metabolism in the striatum of parkinsonian rats grafted with genetically-modified human astrocytes
92. Astrocytes promote or impair the survival and function of embryonic ventral mesencephalon co-grafts: Effects of astrocyte age and expression of recombinant brain-derived neurotrophic factor
93. Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: In vitro characterization and in vivo effects in the rat Parkinson model